Zhongshan Hospital Fudan University
🇨🇳China
Novel Bispecific Antibody KN046 Plus Lenvatinib Shows Promise in Advanced Liver Cancer Treatment
• A phase II trial combining KN046, a bispecific antibody targeting PD-L1/CTLA-4, with lenvatinib achieved a 45.5% objective response rate in advanced hepatocellular carcinoma patients.
• The treatment demonstrated encouraging efficacy with median progression-free survival of 11.0 months and manageable safety profile, though 47.3% of patients experienced grade ≥3 treatment-related adverse events.
• Analysis revealed that circulating tumor DNA status early in treatment may serve as a potential biomarker for predicting treatment response and survival outcomes.
Dapagliflozin and Calorie Restriction Show Promise in Reversing Type 2 Diabetes
• A clinical trial published in The BMJ reveals that combining dapagliflozin with calorie restriction can reverse type 2 diabetes in nearly half the participants.
• The study included over 300 adults in China and showed that 44% of participants in the dapagliflozin group achieved remission, compared to 28% in the placebo group.
• Participants taking dapagliflozin also experienced greater weight loss, improved insulin sensitivity, and better blood pressure and cholesterol levels.
• Experts suggest this approach offers a more accessible strategy for managing type 2 diabetes compared to intensive weight-loss methods or bariatric surgery.
Fruquintinib Plus Sintilimab Shows Promise in Advanced Renal Cell Carcinoma
• A Phase Ib/II trial of fruquintinib plus sintilimab demonstrates promising efficacy in both treatment-naive and previously treated advanced clear cell renal cell carcinoma (ccRCC) patients.
• In treatment-naive patients, the combination therapy achieved a confirmed objective response rate (ORR) of 68.2% with an 18-month progression-free survival rate of 59.4%.
• Previously treated patients experienced a 60.0% confirmed ORR and a median progression-free survival of 15.9 months with the fruquintinib and sintilimab regimen.
• The combination was generally well-tolerated, with manageable adverse events, supporting further investigation in the ongoing Phase III FRUSICA-02 study.
HELP Therapeutics' iPSC-Derived Cell Therapy, HiCM-188, Receives FDA IND Clearance for End-Stage Heart Failure Trial
• HELP Therapeutics received FDA clearance for its IND application for HiCM-188, an allogeneic human iPSC-derived cardiomyocyte therapy.
• The Phase I study will evaluate the safety and tolerability of HiCM-188 transplantation in patients with end-stage heart failure.
• HiCM-188 represents a potential innovative approach, shifting from whole heart transplants to precise myocardial repair via cell injection.
• This marks the first U.S. clinical evaluation of an iPSC-derived cell therapy for end-stage heart failure, offering hope for unmet clinical needs.
© Copyright 2025. All Rights Reserved by MedPath